Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 2Lymphoid 1

Conditions

Lymphoma, Follicular 1Hemophilia A 1

Interventions

Rituximab 1372Cyclophosphamide 1299Vincristine 664Doxorubicin 585Etoposide 525Prednisone 506Cytarabine 482fludarabine 462Methotrexate 442Dexamethasone 412fludarabine phosphate 396Lenalidomide 347Filgrastim 342Bendamustine Hydrochloride 275Radiotherapy 266venetoclax 255ibrutinib 249Peripheral Blood Stem Cell Transplantation 233Melphalan 229obinutuzumab 228Granulocyte Colony-Stimulating Factor 212Bortezomib 204Gemcitabine 201Busulfan 186Whole-Body Irradiation 185Mycophenolic Acid 174Tacrolimus 164Specimen Handling 163Magnetic Resonance Spectroscopy 151Calcium Dobesilate 151

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Factor VIII × Lymphoid × Clear all
NCT00037544 2008-04-22

Study Evaluating ReFacto AF in Severe Hemophilia A

Wyeth is now a wholly owned subsidiary of Pfizer

Phase 3 Completed
Classical hematologyLymphoid

Hemophilia A, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡